AN2 Enterprise Value from 2010 to 2024

ANTX Stock

USD 1.39 0.05 3.73%

AN2 Therapeutics Enterprise Value yearly trend continues to be fairly stable with very little volatility. Enterprise Value will likely drop to about 235.3 M in 2024. Enterprise Value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. View All Fundamentals

Enterprise Value

First Reported

2010-12-31

Previous Quarter

467.9 M

Current Value

235.3 M

Quarterly Volatility

61.1 M

Credit Downgrade

Yuan Drop

Covid

Check AN2 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AN2 Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 73.1 M, Interest Expense of 620.7 K or Selling General Administrative of 7.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.68. AN2 financial statements analysis is a perfect complement when working with AN2 Therapeutics Valuation or Volatility modules.

Check out the analysis of AN2 Therapeutics Correlation against competitors.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

Latest AN2 Therapeutics' Enterprise Value Growth Pattern

Below is the plot of the Enterprise Value of AN2 Therapeutics over the last few years. Enterprise Value (or EV) is usually referred to as AN2 Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on AN2 Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of AN2 Therapeutics value than its market capitalization because it takes into account all of AN2 Therapeutics existing debt. It is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. AN2 Therapeutics' Enterprise Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AN2 Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (55.21 M)

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Enterprise Value

Timeline

AN2 Enterprise Value Regression Statistics

	Arithmetic Mean	283,944,683
	Geometric Mean	278,159,931
	Coefficient Of Variation	21.50
	Mean Deviation	24,607,004
	Median	283,722,704
	Standard Deviation	61,062,032
	Sample Variance	3728.6T
	Range	310.2M
	R-Value	0.03
	Mean Square Error	4012.1T
	R-Squared	0.0008
	Significance	0.92
	Slope	391,268
	Total Sum of Squares	52200T

AN2 Enterprise Value History

	2024	235.3 M
	2023	467.9 M
	2022	157.7 M
	2021	276.5 M
	2020	284.5 M

Other Fundumenentals of AN2 Therapeutics

	Enterprise Value Over E B I T D A
	Enterprise Value Multiple

AN2 Therapeutics Enterprise Value component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Net Invested Capital	Net Working Capital	Deferred Long Term Liab	Short Term Debt	Net Receivables
Total Assets		0.75	0.78	-0.88	-0.92	0.93	0.33	1.0	0.83	0.99	-0.56	-0.56	-0.56
Total Stockholder Equity	0.75		1.0	-0.73	-0.87	0.87	-0.27	0.74	0.98	0.76	-0.79	-0.79	-0.79
Net Tangible Assets	0.78	1.0		-0.78	-0.89	0.89	-0.22	0.78	0.99	0.8	-0.77	-0.77	-0.77
Net Debt	-0.88	-0.73	-0.78		0.8	-0.87	-0.24	-0.92	-0.8	-0.93	0.45	0.45	0.45
Retained Earnings	-0.92	-0.87	-0.89	0.8		-0.99	-0.21	-0.9	-0.94	-0.92	0.84	0.84	0.84
Accounts Payable	0.93	0.87	0.89	-0.87	-0.99		0.24	0.93	0.93	0.96	-0.79	-0.79	-0.79
Total Liab	0.33	-0.27	-0.22	-0.24	-0.21	0.24		0.35	-0.12	0.37	-0.02	-0.02	-0.02
Total Current Assets	1.0	0.74	0.78	-0.92	-0.9	0.93	0.35		0.82	0.99	-0.53	-0.53	-0.53
Net Invested Capital	0.83	0.98	0.99	-0.8	-0.94	0.93	-0.12	0.82		0.84	-0.81	-0.81	-0.81
Net Working Capital	0.99	0.76	0.8	-0.93	-0.92	0.96	0.37	0.99	0.84		-0.59	-0.59	-0.59
Deferred Long Term Liab	-0.56	-0.79	-0.77	0.45	0.84	-0.79	-0.02	-0.53	-0.81	-0.59		1.0	1.0
Short Term Debt	-0.56	-0.79	-0.77	0.45	0.84	-0.79	-0.02	-0.53	-0.81	-0.59	1.0		1.0
Net Receivables	-0.56	-0.79	-0.77	0.45	0.84	-0.79	-0.02	-0.53	-0.81	-0.59	1.0	1.0

Click cells to compare fundamentals

About AN2 Therapeutics Financial Statements

AN2 Therapeutics investors use historical fundamental indicators, such as AN2 Therapeutics' Enterprise Value, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AN2 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Enterprise Value Over EBITDA	95.44	100.21
Enterprise Value Multiple	95.44	100.21
Enterprise Value	467.9 M	235.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC